Abera Bioscience

Abera Bioscience Financial Leverage

The Financial Leverage (Equity Multiplier) of Abera Bioscience (ABERA.SL) as of Oct 16, 2026 is 1.48. In the previous year, Financial Leverage (Equity Multiplier) was 1.57 — a change of -5.75% (lower).

Financial Leverage

1.48

YoY

-5.75%

Last updated:

Financial Leverage (Equity Multiplier) of Abera Bioscience is 2025 1.48 . Financial Leverage (Equity Multiplier) of Abera Bioscience was 2024 1.57 . It decreases by -5.75% lower compared to the previous year.

The Abera Bioscience Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
6.10 SEK
Jan 1, 2019
1.20 SEK
Jan 1, 2020
6.93 SEK
Jan 1, 2021
1.08 SEK
Jan 1, 2022
1.17 SEK
Jan 1, 2023
1.65 SEK
Jan 1, 2024
1.57 SEK
Jan 1, 2025
1.48 SEK
The Abera Bioscience Financial Leverage history
YEARFinancial LeverageYoY
1.48-5.75%
1.57-4.93%
1.65+41.70%
1.17+8.40%
1.08-84.47%
6.93+477.28%
1.20-80.31%
6.10+367.00%
1.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Abera Bioscience Stock analysis

What does Abera Bioscience do? Abera Bioscience AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company focuses on the research and development of pharmaceutical products, particularly in the field of vaccine development. It utilizes a proprietary vaccine delivery platform to advance vaccine candidates toward late pre-clinical or early clinical stages. Abera Bioscience aims to identify licensing partners for further development of its vaccine candidates. The company's technology is primarily applied in the development of vaccines targeting pneumococci and immunooncology. Abera Bioscience has a small operational footprint, employing five full-time staff members. It completed its initial public offering (IPO) on February 24, 2021, and is listed under the ticker ABERA.SL with ISIN SE0015245097. The company's headquarters are located in Uppsala, and it operates primarily within the Nordic market. Its website is https://aberabio.com/. The company's activities are centered on advancing vaccine candidates through its platform technology, with an emphasis on strategic partnerships for subsequent development phases. Abera Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Abera Bioscience stock

Financial Leverage (Equity Multiplier) of Abera Bioscience is 1.48 in 2025.

Financial Leverage (Equity Multiplier) of Abera Bioscience changed from 1.57 to 1.48, representing a -5.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Abera Bioscience since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Abera Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Abera Bioscience

All Key Metrics — Abera Bioscience